SCHEMBL6614486

SCHEMBL6614486

Fc1ccc(-c2cc(N3CCN4CCC3CC4)no2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.52
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
ACKR3 P25106 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
HTR3A P46098 2/20 0.41
CHRNA1 P02708 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
KMT2A Q03164 2/20 0.41
KCNH2 Q12809 1/20 0.41
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6140198 0.99 CHRNA7 (0.51) CHRNA7NPC1RAB9AMAPTTP53
SCHEMBL6610846 0.88 NPC1 (0.43) CHRNA7NPC1RAB9ATP53HTR3A
SCHEMBL6612205 0.88 CHRNA7 (0.43) CHRNA7NPC1RAB9ATDP1HTR3A
Bromide SCHEMBL6139821 0.87 NPC1 (0.42) CHRNA7NPC1RAB9ATP53HTR3A
Bromide SCHEMBL6140035 0.86 CHRNA7 (0.42) CHRNA7NPC1RAB9ATDP1HTR3A
SCHEMBL6615791 0.80 HRH3 (0.40) CHRNA7HTR3ACHRNB4CHRNA3KCNH2
SCHEMBL6610561 0.79 AR (0.39) CHRNA7NPC1RAB9AMAPT
Bromide SCHEMBL6139678 0.79 HRH3 (0.39) CHRNA7HTR3ACHRNB4CHRNA3KCNH2
Bromide SCHEMBL6140069 0.78 AR (0.39) CHRNA7NPC1RAB9AMAPT
SCHEMBL6611520 0.77 RAB9A (0.48) NPC1RAB9AMAPTTP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289986-B1 1,4-DIAZABICYCLO 3.2.2]NONANE-PHENYLISOXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SYNTHELABO (FR) 2004-04-28 EP disclosed
US-20030114461-A1 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof SANOFI (FR) 2003-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114461-A1 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof CYC1, GLRA1, CBR1 CHRNA7 207/4885NPC1 874/4885RAB9A 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.